Business Context and Reporting Period
This Form 8-K filing by Salarius Pharmaceuticals, Inc. (SLRX) reports a material definitive agreement entered into on October 24, 2019. The company is an emerging growth company incorporated in Delaware. Note: The request metadata referenced "Decoy Therapeutics Inc.," but the filing text explicitly identifies the registrant as Salarius Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Agreement Type: Common Stock Purchase Agreement and Registration Rights Agreement with Aspire Capital Fund, LLC.
- Total Commitment: Up to $10.9 million in aggregate common stock over a 30-month term.
- Initial Proceeds: $1,000,000 raised from the sale of 210,526 shares at $4.75 per share.
- Commitment Fee: 101,810 shares of common stock issued concurrently as consideration for entering the agreement.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Covenants: None. There are no financial or business covenants, restrictions on future funding, or limitations on the use of proceeds.
Material Changes and Transaction Mechanics
The filing details a new equity financing mechanism allowing Salarius to sell shares at its discretion. Key mechanics include:
- Purchase Price: The lesser of the lowest sale price on the purchase date or the average of the three lowest closing prices over the preceding 10 trading days.
- Volume Limits: Up to 50,000 shares per business day (up to $500,000 aggregate), with potential mutual agreement to increase to 2,000,000 shares.
- VWAP Option: The company may issue a Volume-Weighted Average Price (VWAP) purchase notice for up to 30% of the day's trading volume at 97% of the VWAP.
- Price Floor: No sales may occur if the closing sale price is less than $0.25.
- Termination: The company may terminate the agreement at any time without cost.
Outlook, Risks, and Management Commentary
Management has secured a flexible funding source to support operations without immediate dilution beyond the initial tranche and commitment fee. The agreement includes a prohibition on Aspire Capital engaging in short-selling or hedging of the company's stock during the term. The company filed a prospectus supplement under its effective shelf registration statement (Form S-3) to register the shares.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction (initial sale + commitment fee shares).
- Review the attached Exhibit 10.1 (Purchase Agreement) for specific conditions precedent to future sales.
- Monitor the company's stock price relative to the $0.25 floor to assess the availability of future funding under this agreement.
- Confirm the status of the shelf registration statement (File No. 333-231010) referenced in the filing.